320 related articles for article (PubMed ID: 33500640)
21. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.
Wu R; Sun J; Xu W; Hu Q; Li W; Xiao J; Yang F; Zeng X; Zeng Y; Zhou J; Matytsina I; Zhang S; Pluta M; Yang R
Ther Clin Risk Manag; 2020; 16():567-578. PubMed ID: 32606716
[TBL] [Abstract][Full Text] [Related]
22. A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A.
Ahuja S; Biss T; Maas Enriquez M; Mancuso ME; Steele M; Kenet G
Eur J Haematol; 2024 May; 112(5):756-764. PubMed ID: 38193596
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
F1000Res; 2021; 10():1049. PubMed ID: 35136579
[No Abstract] [Full Text] [Related]
24. Measurement of extended half-life recombinant FVIII molecules:
Lancellotti S; Sacco M; Tardugno M; Mancuso ME; De Cristofaro R
Res Pract Thromb Haemost; 2023 Feb; 7(2):100070. PubMed ID: 36908765
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities:
Reding MT; Pabinger I; Holme PA; Maas Enriquez M; Mancuso ME; Lalezari S; Miesbach W; Di Minno G; Klamroth R; Hermans C
Ther Adv Hematol; 2023; 14():20406207231166779. PubMed ID: 37113811
[TBL] [Abstract][Full Text] [Related]
26. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
27. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
29. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).
Klamroth R; Hampton K; Saulyte Trakymienė S; Korsholm L; Carcao M
Patient Prefer Adherence; 2021; 15():2443-2454. PubMed ID: 34764641
[TBL] [Abstract][Full Text] [Related]
30. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
[TBL] [Abstract][Full Text] [Related]
31. Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.
Sanabria M; Álvarez Román MT; Castaman G; Janbain M; Matsushita T; Meijer K; Oldenburg J; Friedl S; Reding MT
BMJ Open; 2021 Sep; 11(9):e044997. PubMed ID: 34475142
[TBL] [Abstract][Full Text] [Related]
32. Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C.
Napolitano M; Olsen AA; Nøhr AM; Eichler H
J Blood Med; 2021; 12():9-20. PubMed ID: 33536803
[TBL] [Abstract][Full Text] [Related]
33. Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.
You CW; Baek HJ; Park SK; Park YS; Shin HJ; Engl W; Tangada S
Blood Res; 2019 Sep; 54(3):198-203. PubMed ID: 31730687
[TBL] [Abstract][Full Text] [Related]
34. Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.
John MJ; Chakrabarti P; Apte S; Bhattacharyya M; S C; Hansen T; Kolla R; Ross C; Seth T; Siddharthan N; Abraham A
Res Pract Thromb Haemost; 2020 Nov; 4(8):1324-1330. PubMed ID: 33313471
[TBL] [Abstract][Full Text] [Related]
35. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
36. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A.
Tiede A; Hampton K; Jiménez-Yuste V; Young G; Benchikh El Fegoun S; Chowdary P
Haemophilia; 2022 Jan; 28(1):27-35. PubMed ID: 34562332
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Horling FM; Reipert BM; Allacher P; Engl W; Pan L; Tangada S
Blood Adv; 2024 Jun; 8(11):2726-2739. PubMed ID: 38564770
[TBL] [Abstract][Full Text] [Related]
38. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
Pocoski J; Li N; Ayyagari R; Church N; Maas Enriquez M; Xiang Q; Kelkar S; Du EX; Wu EQ; Xie J
J Blood Med; 2016; 7():129-37. PubMed ID: 27445511
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Reding MT; Simpson M; Ducore J; Holme PA; Maas Enriquez M; Mancuso ME
Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38599195
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
